Br J Urol. 1985 Dec;57(6):680-5. doi: 10.1111/j.1464-410x.1985.tb07031.x.
Four hundred and seventeen patients with newly diagnosed superficial bladder tumours (Ta or T1) were treated with complete transurethral resection and then randomised between three groups. Group 1 had an instillation of 30 mg thiotepa at the time of primary treatment. Group 2 had instillations of thiotepa at 3-monthly intervals for a year. Group 3 was given no instillation. Regular check cystoscopies revealed no significant difference in the rate at which tumours recurred in the three groups (p = 0.4 and P = 0.7 for control vs thiotepa given once and five times respectively). It was concluded that neither thiotepa regimen produced sufficient improvement to justify its use in this group of patients.
417例新诊断的浅表性膀胱肿瘤（Ta或T1）患者接受了经尿道完全切除术，然后随机分为三组。第1组在初次治疗时灌注30mg噻替哌。第2组每隔3个月灌注一次噻替哌，共一年。第3组不进行灌注。定期膀胱镜检查显示，三组肿瘤复发率无显著差异（对照组与单次和五次给予噻替哌组相比，p分别为0.4和0.7）。结论是，两种噻替哌治疗方案均未产生足够的改善效果，不足以证明其在这类患者中的应用合理性。
